Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial (OxHARP)
Oxford Haemodynamic Adaptation to Reduce Pulsatility: Randomised, Placebo-controlled, Double-blind Crossover Trial of Effects of Sildenafil on Cerebral Arterial Pulsatility in Patients With Cryptogenic or Lacunar Stroke and Small Vessel Disease
Sponsor: University of Oxford
Listed as NCT03855332, this PHASE2 trial focuses on Small Vessel Cerebrovascular Disease and remains completed. Sponsored by University of Oxford, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Feb 2023 — Mar 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jun 2021 — Feb 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Oxford
- Wellcome Trust
For direct contact, visit the study record on ClinicalTrials.gov .